NCT04460703 is a NA clinical trial of Control message in Vaccination, sponsored by Yale University.

Who is sponsoring NCT04460703?

NCT04460703 is sponsored by Yale University.

What drugs are being tested in NCT04460703?

Interventions in NCT04460703: Control message, Baseline message, Personal freedom message, Economic freedom message, Self-interest message, Community interest message, Economic benefit message, Guilt message, Embarrassment message, Anger message, Trust in science message, Not bravery message.

What condition does NCT04460703 study?

NCT04460703 studies Vaccination, COVID-19.

Is NCT04460703 still recruiting?

NCT04460703 is currently completed. Last updated 5 May 2022.

Last reviewed 2022-05-05 · How we verify

NCT04460703

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

COVID-19 Vaccine Messaging, Part 1

Completed NA Last updated 5 May 2022

What this trial tests

NA trial testing Control message in Vaccination in 4,000 participants. Completed in 8 July 2020.

Timeline

3 July 2020

Primary endpoint
8 July 2020

8 July 2020

Quick facts

Lead sponsor	Yale University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	other
Enrollment	4,000
Start date	3 July 2020
Primary completion	8 July 2020
Estimated completion	8 July 2020
Sites	1 location across United States

Drugs / interventions tested

Control message
Baseline message
Personal freedom message
Economic freedom message
Self-interest message
Community interest message
Economic benefit message
Guilt message
Embarrassment message
Anger message
Trust in science message
Not bravery message

Conditions studied

Vaccination — all drugs for Vaccination →
COVID-19 — all drugs for COVID-19 →

Sponsor

Yale University

Who can join

18 and older, any sex, with Vaccination or COVID-19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study tests different messages about vaccinating against COVID-19 once the vaccine becomes available. Participants are randomized to 1 of 12 arms, with one control arm and one baseline arm. We will compare the reported willingness to get a COVID-19 vaccine at 3 and 6 months of it becoming available between the 10 intervention arms to the 2 control arms. Study participants are recruited online by Lucid, which matches census based sampling in online recruitment.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Persuasive messaging to increase COVID-19 vaccine uptake intentions.
James EK, Bokemper SE, Gerber AS, Omer SB, et al · · 2021 · cited 56× · PMID 34774363 · DOI 10.1016/j.vaccine.2021.10.039
Interventions to increase COVID-19 vaccine uptake: a scoping review.
Andreas M, Iannizzi C, Bohndorf E, Monsef I, et al · · 2022 · cited 24× · PMID 35920693 · DOI 10.1002/14651858.cd015270

Verify or expand the search:

Other trials of Control message

Trials testing the same drug.

NCT07199660 — Reactions to Social Media Warning Labels Among Teens and Young Adults · NA · completed
NCT06787937 — Communicating About Nicotine Reduction in Cigarettes · NA · recruiting
NCT04740008 — Impact of Low Nicotine Cigarette Messaging on Perceptions and Cigarette Choices · EARLY_PHASE1 · completed

Other recruiting trials for Vaccination

Currently open trials in the same condition.

NCT07236034 — ARISe at UMass Chan · NA · recruiting
NCT07240558 — Pandemic Influenza Vaccine in Organ Transplantation (PIVOT Trial) · Phase 3 · recruiting
NCT07261280 — Testing a Biometric Identification System to Improve Malaria Vaccine Completion · NA · recruiting
NCT07372950 — Kaiser Colorado Flu Nudge · NA · active not recruiting
NCT07085611 — Neutralizing Power of Serum Antibodies - 2 · NA · recruiting

Other Yale University trials

Trials by the same sponsor.

NCT06900998 — Pilot Study: Effects of Nimodipine on Alcohol Drinking · Phase 2 · not yet recruiting
NCT04910984 — Developing a Chatbot to Promote HIV Testing · NA · not yet recruiting
NCT07458087 — Accuracy of the Accuro 3S · NA · not yet recruiting
NCT07398404 — A Multiple Health Behavior Change (MHBC) Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Pa · Phase 1, PHASE2 · not yet recruiting
NCT07305324 — Improving Liver Fibrosis Diagnosis in Primary Care Using FibroX AI · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04460703 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Yale University
Last refreshed: 5 May 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04460703.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing